

# National Medical Care Co

Healthcare : Industrial  
CARE AB: Saudi Arabia  
27 March 2023



**US\$1.076bn** Market Cap  
**50.78%** Free Float  
**US\$4.99mn** Avg. Daily Volume

**Target price** 83.00 **7.7% below current**  
**Current price** 90.00 **as at 27/03/2023**

Research Department  
**Madhu Appissa, CFA**

Tel +966 11 834 5486, [Appissam@alrajhi-capital.com](mailto:Appissam@alrajhi-capital.com)


Existing rating

**Underweight** **Neutral** **Overweight**

## National Medical Care Co.

### Valuation discount is justified in our view

#### Performance (Rebased to 100)



#### Earnings

(SARmn)	2022A	2023E	2024E
Revenue	918	991	1,134
Revenue growth	9%	8%	14%
Gross profit	290	307	355
Gross margin	32%	31%	31%
Operating Profit	189	194	222
Op. margin	21%	20%	20%
Net profit	170	176	195
Net margin	19%	16%	16%
EPS	3.79	3.92	4.35
Adjusted EPS*	NA	3.59	3.97
DPS	1.00	1.00	1.25
Payout ratio	26%	26%	29%
EV/EBITDA	14.1x	12.4x	10.7x
P/E	23.7x	23.0x	20.7x
Adjusted P/E	NA	25.1x	22.7x
RoE	14.2%	13.3%	13.5%

Note: \*Adjusted EPS includes normalised credit loss provision

Source: Company data, Al Rajhi Capital.

Care's 2022 operating results were the best in the last decade with margins touching its highest level in a decade (gross margins of 31.6%, 10 year average has been 25%). The sharp growth in the utilization levels for both its hospitals aided the company, in Q4 2022 the utilization levels touched 94%, for the year it was 84%. This was fuelled by a recovery in construction activity (helped GOSI patients), mainly in H2 2022, and the sharp growth in insured lives of class B and C customers. The growth in revenues was led by both GOSI referrals as well as insurance clients. Going forward, in 2023, we estimate a topline growth of 8% led by slightly better utilization (in Q1 2022 utilization was weak, thus should improve), contribution from addition of beds at CNH (129 new beds), and some contribution from Jiwar in H2 2023. However, we assume slight pressure on margins due to rising manpower costs, higher depreciation related to medical equipments, and costs related to CNH expansion. As we incorporate the latest results as well as the expansion plans in our model, we raise our target price to SAR 83/share (from SAR 65/share). The implied P/E on our target price is 22x based on our adjusted blended average EPS of 2023/2024 (adjusted for credit loss provisions). Despite the sector average about 35x, we believe Care should trade at a discount for the reasons mentioned in the note.

#### Why should Care trade at a discount?

- **Adjusted P/E higher if accounted for full provisions:** Care does not provide for expected credit losses resulting from its GOSI receivables, as it is a major shareholder in the company. If GOSI receivables had to be treated in a similar way as receivables from the other entities, then provisions should increase. If we assume 2.5% (industry standard 2-3%) as the provision for expected credit loss, then the provisions will rise to SAR 25 m (current estimate: SAR 10 m) and SAR 28 m (SAR 11 m) in 2023e and 2024e, respectively. On an adjusted basis, the blended average EPS of 2023/2024e will decline to SAR 3.78/share from SAR 4.13/share, implying a target P/E multiple of almost 22x instead of 20x.
- **Industry P/E skewed by Habib:** The healthcare industry trades at a P/E of 35x (blended average EPS for 2023/2024e). However, if we remove Habib and consider only Mouwasat, Dallah and Hammadi, then based on our EPS estimates, the industry P/E will drop to 30x. Given that Dallah and Mouwasat are expected to post double digit growth, they deserve to trade at high valuations compared to its history. Thus, the right comparable is Hammadi that trades at 26x P/E. Hammadi is expected to grow by 7% versus Care's 6% for the next three years. However, the medium-term potential of Hammadi (once Olaya hospital is ready) is much better than Care, we expect net income CAGR of 17% for Hammadi during 2026-28e once the Olaya hospital is ready. Both the hospitals have bought land in Narjes, thus growth from new hospital in Narjes should be similar. Moreover, Hammadi's Nuzha hospital is one of the most efficiently run hospitals, has manageable working capital requirement and has scope for increasing prices to drive the topline and margins.

We believe Care should trade at a discount to Hammadi. On an adjusted P/E (adj. for credit loss provisions), Care's implied P/E at our target price of SAR 83/share is 22x, 17% discount to the current multiple of Hammadi and 25% discount to our target multiple of Hammadi (29.5x).

- High working capital requirement:** Due to the high receivable period, the company needs notable working capital (net working capital days between 150-200 days). As the company has not invested in the recent times, its high cash balance is aiding it to manage its working capital needs and does not require financing. However, as the company plans to acquire companies and make investments related to Narjes hospital, the cash balance will decline, and the company will have to resort to working capital financing. Thus, the impact of high working capital requirement will be visible in the P&L in the form of financing costs in the coming years.
- GOSI Receivables:** In 2022, around 36% of the revenues were generated from GOSI patients. The company has about SAR 542 m of receivables pending from GOSI, of which bulk is over 270 days. Although, the company has confirmed that they will receive the entire amount and has no plan to account for any write offs, the concern over receivables should remain an overhang on the valuations, in our view.
- Low return ratios and low future growth:** The company has a track record of weak return ratios. During 2017-2021, the return on equity averaged around 9.0%, below its cost of equity. In the last couple of years, the RoE's have improved, in 2022e it touched 14% when the company generated its best operating results. The healthcare industry in KSA generates a RoE of about 20% (ex- Saudi German hospital). In terms of growth also, Care is a laggard, it is expected to grow its net income by 6.0% in the next three years versus 13% for the industry (15% growth if Hammadi excluded).

**Valuations:** As mentioned above, we value Care at a P/E multiple of 22x on its adjusted EPS for 2023/2024 (blended average). We are adjusting for the increase in credit loss provisions if the company treats GOSI receivables in the similar way as it treats other entities. We see Hammadi as the right comparable for the company. We assign a discount of 25% to our target multiple for Hammadi of 29.5x, that results in the 22x P/E multiple for Care. Based on the relative valuation methodology, our fair value for Care is SAR 83/share, that implies a downside of 7.7% from the current levels. Thus, we maintain our neutral recommendation on the stock.

#### Relative valuation methodology

Forward P/E	22.0x
2023e/2024E adj. EPS	3.8
<b>Value per share</b>	<b>83</b>
CMP (as of 27 March 2023)	90
<b>Upside/(Downside)</b>	<b>-7.7%</b>

Source: Al Rajhi Capital Estimates

## IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Al Rajhi Capital (Al Rajhi), a company authorized to engage in securities activities in Saudi Arabia. Al Rajhi is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Rosenblatt Securities Inc, 40 Wall Street 59th Floor, New York NY 10005, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through Al Rajhi. Rosenblatt Securities Inc. accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Rosenblatt Securities Inc. and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

## Ownership and Material Conflicts of Interest

Rosenblatt Securities Inc. or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Rosenblatt Securities Inc, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Rosenblatt Securities Inc. is not aware of any material conflict of interest as of the date of this publication.

## Compensation and Investment Banking Activities

Rosenblatt Securities Inc. or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

## Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither Al Rajhi nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Al Rajhi may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of Al Rajhi.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by Al Rajhi with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of Al Rajhi and Al Rajhi accepts no liability whatsoever for the actions of third parties in this respect. This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain

# National Medical Care Co

Healthcare : Industrial

27 March 2023



investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.

## Disclaimer and additional disclosures for Equity Research

### Disclaimer

This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.

### Explanation of Al Rajhi Capital's rating system

Al Rajhi Capital uses a three-tier rating system based on absolute upside or downside potential for all stocks under its coverage except financial stocks and those few other companies not compliant with Islamic Shariah law:

"Overweight": Our target price is more than 10% above the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Neutral": We expect the share price to settle at a level between 10% below the current share price and 10% above the current share price on a 12 month time horizon.

"Underweight": Our target price is more than 10% below the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Target price": We estimate target value per share for every stock we cover. This is normally based on widely accepted methods appropriate to the stock or sector under consideration, e.g. DCF (discounted cash flow) or SoTP (sum of the parts) analysis.

Please note that the achievement of any price target may be impeded by general market and economic trends and other external factors, or if a company's profits or operating performance exceed or fall short of our expectations.

### Contact us

**Mazen AlSudairi, CFA**  
Head of Research  
Tel : +966 11 836 5468  
Email: [alsudairim@alrajhi-capital.com](mailto:alsudairim@alrajhi-capital.com)

**Al Rajhi Capital**  
Research Department  
Head Office, King Fahad Road  
P.O. Box 5561, Riyadh 11432  
Kingdom of Saudi Arabia  
Email: [research@alrajhi-capital.com](mailto:research@alrajhi-capital.com)  
**Al Rajhi Capital is licensed by the Saudi Arabian Capital Market Authority, License No. 07068/37**